bmiMD
Clinical weight-loss telehealth via Semaglutide + Tirzepatide compounds — same active ingredients as Wegovy and Mounjaro at telehealth pricing.
Clinically-backed telehealth GLP-1 program at meaningfully lower price than direct-to-consumer brand-name Wegovy or Mounjaro — same active ingredients, lower friction.
bmiMD entered the GLP-1 telehealth segment in 2023 with a clear positioning: same Semaglutide and Tirzepatide compounds as Wegovy and Mounjaro, delivered via compounding-pharmacy partnerships at meaningfully lower monthly cost. The clinical efficacy of the underlying compounds is the same — what differs is sourcing (compounding pharmacies vs branded retail), price ($199-499/mo vs $1,000+/mo retail), and convenience (telehealth vs in-clinic).
For longevity buyers, GLP-1 fits a narrow but increasingly important segment: metabolic-health work where weight is a significant lever and dietary intervention alone hasn't closed the gap. The 2024-2026 longevity research has rapidly elevated GLP-1s from pure-weight-loss to metabolic-aging interventions, with cardiovascular + cognitive + inflammation benefits documented across multiple studies.
The LV-relevant frame: bmiMD competes with Hims, Henry Meds, ShedRX, and Levity in the GLP-1 telehealth segment. The differentiator is pricing transparency + clinical-MD oversight + the program structure (titration support, side-effect coaching, monthly check-ins). The honest take: if you want GLP-1 access without paying brand-name retail, bmiMD is one of 4-5 credible options in the category.
Buyers ready for GLP-1 medical intervention who want telehealth access at meaningfully lower cost than retail Wegovy / Mounjaro, with included physician oversight and titration support.
You're unsure GLP-1 is the right intervention — start with diet + exercise + lab work first. Or you have insurance coverage for retail Wegovy / Mounjaro (run those through insurance instead).